ES2983098T3 - Sal y forma cristalina de un compuesto que tiene actividad agonista por el receptor de S1P5 - Google Patents
Sal y forma cristalina de un compuesto que tiene actividad agonista por el receptor de S1P5 Download PDFInfo
- Publication number
- ES2983098T3 ES2983098T3 ES20854718T ES20854718T ES2983098T3 ES 2983098 T3 ES2983098 T3 ES 2983098T3 ES 20854718 T ES20854718 T ES 20854718T ES 20854718 T ES20854718 T ES 20854718T ES 2983098 T3 ES2983098 T3 ES 2983098T3
- Authority
- ES
- Spain
- Prior art keywords
- crystal
- powder
- compound
- diffraction
- diffraction spectrum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962889091P | 2019-08-20 | 2019-08-20 | |
| PCT/JP2020/031326 WO2021033729A1 (ja) | 2019-08-20 | 2020-08-19 | Ｓ１ｐ５受容体作動活性を有する化合物の塩および結晶形 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2983098T3 true ES2983098T3 (es) | 2024-10-22 |
Family
ID=74660224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20854718T Active ES2983098T3 (es) | 2019-08-20 | 2020-08-19 | Sal y forma cristalina de un compuesto que tiene actividad agonista por el receptor de S1P5 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US12459890B2 (https=) |
| EP (1) | EP4019496B1 (https=) |
| JP (1) | JP7409383B2 (https=) |
| KR (1) | KR102930707B1 (https=) |
| CN (1) | CN114302873A (https=) |
| BR (1) | BR112022002632A2 (https=) |
| CA (1) | CA3150303A1 (https=) |
| ES (1) | ES2983098T3 (https=) |
| IL (1) | IL290432A (https=) |
| MX (1) | MX2022001820A (https=) |
| MY (1) | MY207001A (https=) |
| PH (1) | PH12022550319A1 (https=) |
| TW (1) | TWI859303B (https=) |
| WO (1) | WO2021033729A1 (https=) |
| ZA (1) | ZA202201784B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3757091T (pt) * | 2018-02-22 | 2024-09-11 | Ono Pharmaceutical Co | Ácido 1-[[(3s)-3-metil-6-(4,4,4-trifluorobutoxi)-3,4-di-hidronaftalen-2-il]metil]azetidino-3-carboxílico com atividade agonista do recetor s1p5 para o tratamento de doenças neurodegenerativas e cancro |
| AU2022291768A1 (en) | 2021-06-16 | 2023-11-30 | Celgene Corporation | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
| EP4633736A1 (en) * | 2022-12-16 | 2025-10-22 | Celgene Corporation | Heterocyclic compounds as modulators of s1p5 |
| WO2025119254A1 (en) * | 2023-12-06 | 2025-06-12 | Ono Pharmaceutical Co., Ltd. | Method for preparing dihydronaphthalene derivative |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ234564A (en) * | 1986-11-21 | 1991-04-26 | Haessle Ab | 1-substituted benzimidazoles and pharmaceutical compositions |
| GB8725118D0 (en) * | 1987-10-27 | 1987-12-02 | Ciba Geigy Ag | Rifamycin derivatives |
| JP2005020882A (ja) | 2003-06-25 | 2005-01-20 | Matsushita Electric Works Ltd | モータアクチュエータ装置 |
| US7825109B2 (en) | 2003-08-29 | 2010-11-02 | Ono Pharmaceutical Co., Ltd. | Compound capable of binding S1P receptor and pharmaceutical use thereof |
| KR20110140139A (ko) | 2003-08-29 | 2011-12-30 | 오노 야꾸힝 고교 가부시키가이샤 | Ｓ１ｐ 수용체 결합능을 갖는 화합물 및 그 의약 용도 |
| JP2006064757A (ja) | 2004-08-24 | 2006-03-09 | Systec Kyowa:Kk | ディスプレイ固定用スタンド |
| BRPI0519012A2 (pt) * | 2004-12-13 | 2008-12-23 | Ono Pharmaceutical Co | derivado do Ácido aminocarboxÍlico e seu uso medicinal |
| JP2009526073A (ja) | 2006-02-09 | 2009-07-16 | ユニバーシティ オブ バージニア パテント ファンデーション | 二環式スフィンゴシン−１−リン酸受容体アナログ |
| ME00529B (me) * | 2006-06-12 | 2011-10-10 | Novartis Ag | Polimorfi n-hidroksi-3-[4-[[[2-(-metil-1h-indol-3-il)etil]amino]fenil]-2e-2-propenamida |
| UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
| EA034451B1 (ru) | 2011-02-07 | 2020-02-10 | Байоджен Ма Инк. | Модуляторы s1p |
| EP3228615B1 (en) * | 2014-12-04 | 2021-01-20 | ONO Pharmaceutical Co., Ltd. | Dihydronaphthalene derivatives useful in the treatment of s1p5-mediated diseases |
| EP3409658B9 (en) | 2016-01-29 | 2024-07-17 | ONO Pharmaceutical Co., Ltd. | Tetrahydronaphthalene derivative |
| PT3757091T (pt) * | 2018-02-22 | 2024-09-11 | Ono Pharmaceutical Co | Ácido 1-[[(3s)-3-metil-6-(4,4,4-trifluorobutoxi)-3,4-di-hidronaftalen-2-il]metil]azetidino-3-carboxílico com atividade agonista do recetor s1p5 para o tratamento de doenças neurodegenerativas e cancro |
| TW202114983A (zh) * | 2019-08-20 | 2021-04-16 | 日商小野藥品工業股份有限公司 | Ｓ１ｐ媒介疾病的預防及／或治療劑 |
-
2020
- 2020-08-19 MX MX2022001820A patent/MX2022001820A/es unknown
- 2020-08-19 US US17/634,505 patent/US12459890B2/en active Active
- 2020-08-19 BR BR112022002632A patent/BR112022002632A2/pt unknown
- 2020-08-19 EP EP20854718.2A patent/EP4019496B1/en active Active
- 2020-08-19 PH PH1/2022/550319A patent/PH12022550319A1/en unknown
- 2020-08-19 CN CN202080056980.0A patent/CN114302873A/zh active Pending
- 2020-08-19 JP JP2021540972A patent/JP7409383B2/ja active Active
- 2020-08-19 TW TW109128245A patent/TWI859303B/zh active
- 2020-08-19 ES ES20854718T patent/ES2983098T3/es active Active
- 2020-08-19 KR KR1020227004458A patent/KR102930707B1/ko active Active
- 2020-08-19 MY MYPI2022000691A patent/MY207001A/en unknown
- 2020-08-19 CA CA3150303A patent/CA3150303A1/en active Pending
- 2020-08-19 WO PCT/JP2020/031326 patent/WO2021033729A1/ja not_active Ceased
-
2022
- 2022-02-08 IL IL290432A patent/IL290432A/en unknown
- 2022-02-10 ZA ZA2022/01784A patent/ZA202201784B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI859303B (zh) | 2024-10-21 |
| TW202114984A (zh) | 2021-04-16 |
| MY207001A (en) | 2025-01-23 |
| EP4019496A4 (en) | 2023-01-11 |
| CN114302873A (zh) | 2022-04-08 |
| US20220289675A1 (en) | 2022-09-15 |
| AU2020334489C1 (en) | 2026-03-26 |
| EP4019496A1 (en) | 2022-06-29 |
| JP7409383B2 (ja) | 2024-01-09 |
| JPWO2021033729A1 (https=) | 2021-02-25 |
| WO2021033729A1 (ja) | 2021-02-25 |
| US12459890B2 (en) | 2025-11-04 |
| MX2022001820A (es) | 2022-03-17 |
| KR20220050886A (ko) | 2022-04-25 |
| AU2020334489A1 (en) | 2022-03-03 |
| BR112022002632A2 (pt) | 2022-05-03 |
| KR102930707B1 (ko) | 2026-02-24 |
| AU2020334489B2 (en) | 2025-10-30 |
| IL290432A (en) | 2022-04-01 |
| PH12022550319A1 (en) | 2022-12-19 |
| EP4019496B1 (en) | 2024-06-05 |
| CA3150303A1 (en) | 2021-02-25 |
| NZ785003A (en) | 2024-09-27 |
| ZA202201784B (en) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2983098T3 (es) | Sal y forma cristalina de un compuesto que tiene actividad agonista por el receptor de S1P5 | |
| CA3004372C (en) | Pyrimidine derivative and use thereof | |
| ES2798424T3 (es) | Compuestos de triazolopiridina y usos de estos | |
| JP2013536825A (ja) | ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体 | |
| CA3161892A1 (en) | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | |
| TW201206937A (en) | Organic compounds | |
| AU2025267332A1 (en) | Psychotropic agents and uses thereof | |
| ES2975689T3 (es) | Derivado de tetrahidronaftaleno | |
| TW200900395A (en) | Heteroarylamide pyrimidone compounds | |
| US10590140B2 (en) | Tetrahydropyrimidodiazepine and dihydropyridodiazepine compounds for treating pain and pain related conditions | |
| ES2852724T3 (es) | Derivados de dihidronaftaleno útiles en el tratamiento de enfermedades mediadas por S1P5 | |
| US20230150936A1 (en) | Analogs of n,n,n-trimethyl-4-phosphoryloxytryptamine | |
| US20230018728A1 (en) | Pyrazolo-heteroaryl derivative, preparation method therefor, and medical use thereof | |
| BR112021012950A2 (pt) | Métodos e materiais para aumentar os níveis de polipeptídeo do fator de transcrição eb | |
| US9238632B2 (en) | 3-cyanoanilinoalkylarylpiperazine derivative and use thereof in preparing drugs | |
| ES2682959T3 (es) | Compuestos de 3-benciloxi-biciclo[3.1.0]hexano 4-sustituidos como antagonistas de mGLuR 2/3 | |
| RU2833357C2 (ru) | Соль и кристаллическая форма соединения, обладающего агонистической активностью по отношению к рецептору s1p5 | |
| CN111285843B (zh) | 新型5-羟色胺和去甲肾上腺素双重再摄取抑制剂及其医药用途 | |
| US20090105223A1 (en) | Compound Having Activity Of Blocking NMDA Receptor Channel, and Pharmaceutical Agent Using The Same | |
| AU2020334489C8 (en) | Salt and crystal form of compound having agonistic activity to S1P5 receptor | |
| WO2022125614A1 (en) | Phosphonates as inhibitors of enpp1 and cdnp | |
| HK40069904A (en) | Salt and crystal form of compound having agonistic activity to s1p5 receptor | |
| EP3345898A1 (en) | Crystals of 5-cyclopropyl-2-((1-(3-fluorobenzyl)-1h-indol-5-yl)amino)nicotinic acid | |
| KR20200052938A (ko) | 테트라히드로나프틸우레아 유도체의 결정 | |
| CA3049319A1 (en) | Therapeutic agent for non-motor symptoms associated with parkinson's disease |